PC
SGMO

PointState Capital’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

PointState Capital’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-277,300
Closed -$2.91M – 172
2013
Q3 		$2.91M Buy
+277,300
New +$2.75M 0.05% 120

Other funds holding SGMO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RCI
Ridgeback Capital Investments Miami Beach, Florida $560K AUM
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PointState Capital's SGMO Position: Q4 2013 in Review

PointState Capital sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2013, closing a stake of 277,300 shares — an estimated $2.91M sold.

PointState Capital first reported a position in SGMO in Q3 2013 and held it in 1 quarter. The position peaked at $2.91M in Q3 2013. 115 funds tracked by Wall St. Rank hold SGMO as of Q4 2013.

  • PointState Capital reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2013 after selling out during the quarter.
  • PointState Capital sold 277,300 SANGAMO THERAPEUTICS INC shares in Q4 2013, an estimated $2.91M.
  • PointState Capital first reported a position in SANGAMO THERAPEUTICS INC in Q3 2013 and held it in 1 quarter.
  • PointState Capital's SANGAMO THERAPEUTICS INC position peaked at $2.91M in Q3 2013.
  • 115 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2013.

Based on PointState Capital's 13F filing for Q4 2013, filed 14 Feb 2014.